Minimum Bio
Sydney, Australia· Est.
Fast, agnostic target identification platform using phage display for drug discovery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Fast, agnostic target identification platform using phage display for drug discovery.
OncologyImmunologyNeurologyInfectious Diseases
Technology Platform
Mercurious™ is a phage‑display based platform that creates cDNA‑encoded protein libraries from cellular mRNA, enabling iterative affinity purification and PCR‑like amplification to identify low‑abundance protein targets of bioactive compounds with high specificity.
Opportunities
Strategic partnerships with pharma to provide rapid target deconvolution and expansion into molecular‑glue discovery could unlock substantial revenue streams.
Risk Factors
Reliance on external collaborations for commercial traction and the need to validate scalability and reproducibility across diverse biological systems.
Competitive Landscape
Competes with proteomics and genetic target‑identification services (e.g., affinity‑capture MS, CRISPR screens) but differentiates through low‑abundance protein detection and iterative phage‑display enrichment.